<?xml version='1.0' encoding='utf-8'?>
<document id="24782485"><sentence text="Safety, tolerability, pharmacokinetics and antitumor activity of ganitumab, an investigational fully human monoclonal antibody to insulin-like growth factor type 1 receptor, combined with gemcitabine as first-line therapy in patients with metastatic pancreatic cancer: a phase 1b study."><entity charOffset="188-199" id="DDI-PubMed.24782485.s1.e0" text="gemcitabine" /></sentence><sentence text="Previous Phase 1 studies have shown the acceptable safety profile of ganitumab-a fully human monoclonal antibody to insulin-like growth factor Type 1 receptor-in patients with advanced solid tumors" /><sentence text=" However, ganitumab 20 mg/kg in combination with gemcitabine had not been administered to patients with metastatic pancreatic cancer"><entity charOffset="49-60" id="DDI-PubMed.24782485.s3.e0" text="gemcitabine" /></sentence><sentence text=" To evaluate the safety, tolerability, pharmacokinetics and antitumor activity of ganitumab 20 mg/kg combined with gemcitabine 1000 mg/m(2) as first-line therapy in patients with metastatic pancreatic cancer, we conducted a Phase 1b study"><entity charOffset="115-126" id="DDI-PubMed.24782485.s4.e0" text="gemcitabine" /></sentence><sentence text="" /><sentence text="Eligible patients were adults with previously untreated metastatic adenocarcinoma of the pancreas" /><sentence text=" Patients received gemcitabine 1000 mg/m(2) on Days 1, 8 and 15 plus ganitumab 20 mg/kg on Days 1 and 15 of each 28-day cycle"><entity charOffset="19-30" id="DDI-PubMed.24782485.s7.e0" text="gemcitabine" /></sentence><sentence text=" Gemcitabine was administered intravenously over 30-60 min"><entity charOffset="1-12" id="DDI-PubMed.24782485.s8.e0" text="Gemcitabine" /></sentence><sentence text=" Ganitumab was administered intravenously over 60 min after completing gemcitabine infusion"><entity charOffset="71-82" id="DDI-PubMed.24782485.s9.e0" text="gemcitabine" /></sentence><sentence text="" /><sentence text="Six patients were enrolled and received the study treatment" /><sentence text=" All patients had thrombocytopenia and leukopenia" /><sentence text=" Other most common adverse events were neutropenia and nausea" /><sentence text=" One patient had a dose-limiting toxicity defined as Grade 3 neutropenia with fever" /><sentence text=" Exposure to ganitumab 20 mg/kg was not affected by the administration of gemcitabine"><entity charOffset="74-85" id="DDI-PubMed.24782485.s15.e0" text="gemcitabine" /></sentence><sentence text=" No apparent pharmacokinetic drug-drug interaction was observed" /><sentence text=" No anti-ganitumab antibodies were detected" /><sentence text=" Five patients had a measurable tumor region at baseline" /><sentence text=" Of these, four patients had a best response of stable disease" /><sentence text="" /><sentence text="Ganitumab 20 mg/kg combined with gemcitabine 1000 mg/m(2) was tolerable and showed an acceptable safety profile in patients with untreated metastatic pancreatic cancer"><entity charOffset="33-44" id="DDI-PubMed.24782485.s21.e0" text="gemcitabine" /></sentence><sentence text="" /></document>